- KR₩433bn
- KR₩473bn
- KR₩155bn
- 38
- 13
- 88
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 30.8 | ||
| PEG Ratio (f) | 0.48 | ||
| EPS Growth (f) | 179.22% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.39 | ||
| Price to Tang. Book | 2.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.8 | ||
| EV to EBITDA | 35.78 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.78% | ||
| Return on Equity | 2.51% | ||
| Operating Margin | 2.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 125,258.58 | 132,976.39 | 134,399.28 | 156,677.02 | 154,824.78 | 184,000 | 203,000 | 8.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +34.1 | -14.49 | +156.16 | -32.97 | -85.79 | +609.15 | +40.49 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Company’s products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.
Directors
- Baek Cheon Lee CHM (71)
- Hyeok Jong Lee CEO (45)
- Du Hyeon Kim VPR (60)
- Jun Seok Park MDR (68)
- Su Yong Jin OTH (45)
- Myeong Cheol Lee OTH (54)
- Noboru Inaska OTH (57)
- Myeong Ho Jeon DRC (42)
- Taizan Kawakami DRC (64)
- Shigeki Yamauchi DRC (60)
- Takahiro Yoshikawa DRC (69)
- Yun Ok Choi NID (35)
- Yin Yeong Oh NID (47)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 5th, 1985
- Public Since
- August 7th, 2001
- No. of Shareholders
- 39,421
- No. of Employees
- 390
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 30,924,536
- Address
- 368-3, Dadae-Ro, Saha-Gu, BUSAN, 49469
- Web
- https://www.bi-nex.com/
- Phone
- +82 328503236
- Auditors
- Daejoo Accounting Corp.
Upcoming Events for 053030
Q2 2024 Binex Co Ltd Earnings Release
Similar to 053030
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
Ahn-Gook Pharmaceutical Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
What is the Binex Co share price?
As of Today at 19:04 UTC, shares in Binex Co are trading at KR₩14,010. This share price information is delayed by 15 minutes.
How has the Binex Co share price performed this year?
Shares in Binex Co last closed at KR₩14,010 and the price had moved by +47.57% over the past 365 days. In terms of relative price strength the Binex Co share price has outperformed the FTSE Developed Asia Pacific Index by +54.03% over the past year.
What are the analyst and broker recommendations for Binex Co?
The overall consensus recommendation for Binex Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Binex Co dividend yield?
Binex Co does not currently pay a dividend.
Does Binex Co pay a dividend?
Binex Co does not currently pay a dividend.
When does Binex Co next pay dividends?
Binex Co does not currently pay a dividend.
How do I buy Binex Co shares?
To buy shares in Binex Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Binex Co?
As of the previous close price of KR₩14,010, shares in Binex Co had a market capitalisation of KR₩433bn.
Where are Binex Co shares listed?
Here are the trading details for Binex Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 053030
What kind of share is Binex Co?
Based on an overall assessment of its quality, value and momentum Binex Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Binex Co share price forecast for 2024?
The analyst consensus target price for shares in Binex Co is KR₩16,000. That is 14.2% above the last closing price of KR₩14,010.
Analysts covering Binex Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩405 for the next financial year.
What is the trend in the Binex Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Binex Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +75.81%.
As of the last closing price of KR₩14,010, shares in Binex Co were trading +41.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Binex Co PE Ratio?
The Binex Co PE ratio based on its reported earnings over the past 12 months is 30.8. The shares last closed at KR₩14,010.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Binex Co?
Binex Co's management team is headed by:
- Baek Cheon Lee - CHM
- Hyeok Jong Lee - CEO
- Du Hyeon Kim - VPR
- Jun Seok Park - MDR
- Su Yong Jin - OTH
- Myeong Cheol Lee - OTH
- Noboru Inaska - OTH
- Myeong Ho Jeon - DRC
- Taizan Kawakami - DRC
- Shigeki Yamauchi - DRC
- Takahiro Yoshikawa - DRC
- Yun Ok Choi - NID
- Yin Yeong Oh - NID